Wound healing franchiseGilles called the wound healing results from the Angiogenesis Foundation a "home run" and a possible wound healing franchise has been mentioned. This month will be one year since the announcement of follow on studies with the Angiogenesis Foundation. Given the merger is completed the company is now optimized to bring products to market as it also potentially seeks a partner. PGX is also reaching commercial production.
CZO's July 18, 2023 news release:
“While Ceapro has so far evolved in dermatology by providing active ingredients serving the cosmetic sector, additional expected evidence-based results from this study will not only reinforce and/or add claims to existing cosmetics formulations but should further position Ceapro in dermatology along with a pharmaceutical and medical supplies partner who will benefit from additional selling points arising from this unique research program. This is in line with our vision to expand our business model from an active ingredient provider to a life sciences company,” commented Gilles R. Gagnon, M.Sc., MBA, President and CEO of Ceapro. ----------------------
Avenanthramide and β-Glucan Therapeutics Accelerate Wound Healing Via Distinct and Nonoverlapping Mechanisms - PubMed (nih.gov) Conclusions: AVN and β-Glucan accelerated wound closure compared to controls through distinct mechanisms. AVN-treated scars displayed a more regenerative tissue architecture with reduced inflammatory cell recruitment, while β-Glucan demonstrated increased angiogenesis with more highly aligned tissue architecture more indicative of fibrosis. A deeper understanding of the mechanisms driving healing in these two naturally derived therapeutics will be important for translation to human use.